20 September 2023 - A recent report by the Patented Medicine Prices Review Board shows increased growth for private drug plan costs but promising pharmaceutical innovation, says Joe Farago, executive director of private payers and investment at Innovative Medicines Canada.
The report also found the number of new medicines launched in Canada was higher than the median for Organisation for Economic Co-operation and Development countries, but fell below the median of the 11 PMPRB comparators, all of which have lower average patented medicine prices.